Differential Actions of Vasopeptidase Inhibition Versus Angiotensin-Converting Enzyme Inhibition on Diuretic Therapy in Experimental Congestive Heart Failure | Zendy

Alessandro Cataliotti | Zendy; Guido Boerrigter | Zendy; Horng H. Chen | Zendy; Michihisa Jougasaki | Zendy; Lisa C. Costello | Zendy; Toshihiro Tsuruda | Zendy; Shang-Chiun Lee | Zendy; Lorenzo Malatino | Zendy; John C. Burnett | Zendy

Open Access

Differential Actions of Vasopeptidase Inhibition Versus Angiotensin-Converting Enzyme Inhibition on Diuretic Therapy in Experimental Congestive Heart Failure

Author(s) -

Alessandro Cataliotti,

Guido Boerrigter,

Horng H. Chen,

Michihisa Jougasaki,

Lisa C. Costello,

Toshihiro Tsuruda,

Shang-Chiun Lee,

Lorenzo Malatino,

John C. Burnett

Publication year - 2002

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/hc0502.102962

Subject(s) - heart failure , medicine , diuretic , aldosterone , ace inhibitor , renin–angiotensin system , adrenomedullin , diuresis , endocrinology , plasma renin activity , atrial natriuretic peptide , angiotensin converting enzyme , renal function , blood pressure , receptor

Omapatrilat (OMA), a vasopeptidase inhibitor, simultaneously inhibits angiotensin-converting enzyme (ACE) and neutral endopeptidase, which degrades vasodilatory factors (eg, ADM) and natriuretic peptides. Based on the beneficial cardiorenal and humoral properties of the natriuretic peptides, we hypothesized that an acute vasopeptidase inhibitor with or without diuretic would result in more favorable cardiorenal and hormonal actions than ACE inhibition plus diuretic (ACEI+D) in congestive heart failure.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research